+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Adult Vaccines Market by Vaccine Type, Disease Indication, End User - Global Forecast 2025-2030- Product Image
Adult Vaccines Market by Vaccine Type, Disease Indication, End User - Global Forecast 2025-2030- Product Image
Sale

Adult Vaccines Market by Vaccine Type, Disease Indication, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6015023
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Adult Vaccines Market grew from USD 17.63 billion in 2023 to USD 19.11 billion in 2024. It is expected to continue growing at a CAGR of 8.28%, reaching USD 30.78 billion by 2030.

The adult vaccines market encompasses vaccines specifically formulated for adults to prevent diseases such as influenza, pneumonia, hepatitis, shingles, and HPV, among others. The necessity for adult vaccines arises from the ongoing need to protect the adult population from preventable diseases, which can potentially lead to hospitalizations and increased healthcare costs. The application of these vaccines spans beyond individual health to public health, reducing the spread of infections and contributing to herd immunity. End-use is primarily seen in healthcare settings such as hospitals, clinics, and pharmacies, with some workplaces offering vaccinations to employees. Key growth factors in this market include the rising awareness of vaccination benefits, an increase in government initiatives to promote adult immunization, and the growing prevalence of infectious diseases among the aging population. Additionally, the COVID-19 pandemic has underscored the importance of vaccines, driving innovation and investment in the sector. Consequently, there is potential for significant opportunities in developing new vaccines, distribution technologies, and public education campaigns.

However, limitations include vaccine hesitancy among certain populations, high costs of vaccine development and distribution, and regulatory hurdles that can delay the introduction of new vaccines to the market. Other challenges involve ensuring equitable access to vaccines across different socioeconomic groups and regions. Innovation and research opportunities exist in developing multi-valent vaccines, advancing technology for better storage and distribution, and exploring new delivery methods such as oral or intranasal vaccines. The market's nature is dynamic and increasingly competitive, with a trend towards strategic partnerships and collaborations to enhance research capabilities and market reach. Overall, staying attuned to technological advances and regulatory changes can provide businesses with a strategic advantage in capitalizing on emerging opportunities.

Understanding Market Dynamics in the Adult Vaccines Market

The Adult Vaccines Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Expansion of healthcare infrastructure and access to vaccination services
    • Growing emphasis on preventive healthcare among individuals and communities
    • Emergence of new vaccine-preventable diseases and variants
  • Market Restraints
    • High costs associated with vaccine development and distribution limit market reach
  • Market Opportunities
    • Collaborations with travel industry stakeholders to promote travel vaccines and ensure traveler health
    • Comprehensive immunization programs targeting the aging population to increase vaccine uptake
  • Market Challenges
    • Stringent government regulations and lengthy approval processes hinder vaccine market expansion

Exploring Porter’s Five Forces for the Adult Vaccines Market

Porter’s Five Forces framework further strengthens the insights of the Adult Vaccines Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Adult Vaccines Market

External macro-environmental factors deeply influence the performance of the Adult Vaccines Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Adult Vaccines Market

The Adult Vaccines Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Adult Vaccines Market

The Adult Vaccines Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Adult Vaccines Market

The Adult Vaccines Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Adult Vaccines Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca, Bharat Biotech, BioNTech, CSL Limited, CureVac, Dynavax Technologies, Emergent BioSolutions, GlaxoSmithKline, Inovio Pharmaceuticals, Johnson & Johnson, Merck & Co., Moderna, Novavax, Pfizer, Sanofi, Seqirus, Serum Institute of India, Sinovac Biotech, Valneva SE, and Vaxart.

Market Segmentation & Coverage

This research report categorizes the Adult Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Vaccine Type
    • Inactivated Vaccines
      • Split Virus Vaccines
      • Whole Virus Vaccines
    • Live Attenuated Vaccines
    • Subunit Vaccines
      • Polysaccharide Vaccines
      • Protein Subunit Vaccines
    • Toxoid Vaccines
  • Disease Indication
    • Hepatitis B
    • Herpes Zoster
    • Human Papillomavirus (HPV)
    • Influenza
    • Pneumococcal Disease
  • End User
    • Clinics
    • Homecare Settings
    • Hospitals
    • Vaccination Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Expansion of healthcare infrastructure and access to vaccination services
5.1.1.2. Growing emphasis on preventive healthcare among individuals and communities
5.1.1.3. Emergence of new vaccine-preventable diseases and variants
5.1.2. Restraints
5.1.2.1. High costs associated with vaccine development and distribution limit market reach
5.1.3. Opportunities
5.1.3.1. Collaborations with travel industry stakeholders to promote travel vaccines and ensure traveler health
5.1.3.2. Comprehensive immunization programs targeting the aging population to increase vaccine uptake
5.1.4. Challenges
5.1.4.1. Stringent government regulations and lengthy approval processes hinder vaccine market expansion
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Adult Vaccines Market, by Vaccine Type
6.1. Introduction
6.2. Inactivated Vaccines
6.2.1. Split Virus Vaccines
6.2.2. Whole Virus Vaccines
6.3. Live Attenuated Vaccines
6.4. Subunit Vaccines
6.4.1. Polysaccharide Vaccines
6.4.2. Protein Subunit Vaccines
6.5. Toxoid Vaccines
7. Adult Vaccines Market, by Disease Indication
7.1. Introduction
7.2. Hepatitis B
7.3. Herpes Zoster
7.4. Human Papillomavirus (HPV)
7.5. Influenza
7.6. Pneumococcal Disease
8. Adult Vaccines Market, by End User
8.1. Introduction
8.2. Clinics
8.3. Homecare Settings
8.4. Hospitals
8.5. Vaccination Centers
9. Americas Adult Vaccines Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Adult Vaccines Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Adult Vaccines Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. ADULT VACCINES MARKET RESEARCH PROCESS
FIGURE 2. ADULT VACCINES MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL ADULT VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL ADULT VACCINES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL ADULT VACCINES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. ADULT VACCINES MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. ADULT VACCINES MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. ADULT VACCINES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL ADULT VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ADULT VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. ADULT VACCINES MARKET DYNAMICS
TABLE 7. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ADULT VACCINES MARKET SIZE, BY SPLIT VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ADULT VACCINES MARKET SIZE, BY WHOLE VIRUS VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ADULT VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ADULT VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ADULT VACCINES MARKET SIZE, BY PROTEIN SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ADULT VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ADULT VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ADULT VACCINES MARKET SIZE, BY HERPES ZOSTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ADULT VACCINES MARKET SIZE, BY HUMAN PAPILLOMAVIRUS (HPV), BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ADULT VACCINES MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ADULT VACCINES MARKET SIZE, BY PNEUMOCOCCAL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ADULT VACCINES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ADULT VACCINES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ADULT VACCINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ADULT VACCINES MARKET SIZE, BY VACCINATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. CANADA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 46. CANADA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 47. CANADA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 48. CANADA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 49. CANADA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. MEXICO ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 51. MEXICO ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 52. MEXICO ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 53. MEXICO ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ADULT VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 72. CHINA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 73. CHINA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 74. CHINA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 75. CHINA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 76. CHINA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 77. INDIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 78. INDIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 79. INDIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 80. INDIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 81. INDIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 87. JAPAN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 88. JAPAN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 89. JAPAN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 90. JAPAN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 91. JAPAN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. THAILAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 118. THAILAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 119. THAILAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 120. THAILAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 121. THAILAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ADULT VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 133. DENMARK ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 134. DENMARK ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 135. DENMARK ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 136. DENMARK ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 137. DENMARK ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. EGYPT ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 139. EGYPT ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 140. EGYPT ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 141. EGYPT ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 142. EGYPT ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 143. FINLAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 144. FINLAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 145. FINLAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 146. FINLAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 147. FINLAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 148. FRANCE ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 149. FRANCE ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 150. FRANCE ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 151. FRANCE ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 152. FRANCE ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. GERMANY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 154. GERMANY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 155. GERMANY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 156. GERMANY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 157. GERMANY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. ITALY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 164. ITALY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 165. ITALY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 166. ITALY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 167. ITALY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. NORWAY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 179. NORWAY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 180. NORWAY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 181. NORWAY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 182. NORWAY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 183. POLAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 184. POLAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 185. POLAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 186. POLAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 187. POLAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. QATAR ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 189. QATAR ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 190. QATAR ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 191. QATAR ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 192. QATAR ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. SPAIN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 209. SPAIN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 210. SPAIN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 211. SPAIN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 212. SPAIN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. TURKEY ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 224. TURKEY ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 225. TURKEY ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 226. TURKEY ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 227. TURKEY ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY INACTIVATED VACCINES, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY SUBUNIT VACCINES, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM ADULT VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. ADULT VACCINES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 239. ADULT VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Adult Vaccines Market, which are profiled in this report, include:
  • AstraZeneca
  • Bharat Biotech
  • BioNTech
  • CSL Limited
  • CureVac
  • Dynavax Technologies
  • Emergent BioSolutions
  • GlaxoSmithKline
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Merck & Co.
  • Moderna
  • Novavax
  • Pfizer
  • Sanofi
  • Seqirus
  • Serum Institute of India
  • Sinovac Biotech
  • Valneva SE
  • Vaxart

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages198
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 19.11 Billion
Forecasted Market Value ( USD ) by 2030 $ 30.78 Billion
Compound Annual Growth Rate8.2%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Adult Vaccines Global Market Report 2024 - Product Image

Adult Vaccines Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Adult Vaccine Market Report, Forecast by Disease, Countries and Company Analysis, 2024-2032 - Product Image

Adult Vaccine Market Report, Forecast by Disease, Countries and Company Analysis, 2024-2032

  • Report
  • 200 Pages
  • Global
From
Vaccine Market: Trends, Opportunities and Competitive Analysis [2024-2030] - Product Image

Vaccine Market: Trends, Opportunities and Competitive Analysis [2024-2030]

  • Report
  • 150 Pages
  • Global
From
Vaccines Market by Type, Technology Type, Route of administration, Indication, Age Group - Global Forecast 2025-2030 - Product Image

Vaccines Market by Type, Technology Type, Route of administration, Indication, Age Group - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Multivalent Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Multivalent Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.